Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum -Exposed, Drug-Treated Kenyan Adults
The Journal of Infectious Diseases · 15.09.2025 · 232 (3) · e372-e382
DOI: 10.1093/infdis/jiaf274 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 29.05.2025. Verfasst von Nathanial K Copeland und 25 weiteren Autor:innen. Beteiligte Einrichtung: Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya. Hauptthemen laut MEDLINE: Malaria, Falciparum, Plasmodium falciparum, Antimalarials, Malaria Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bill and Melinda Gates Foundation, Gates Foundation.
Abstract (Originalsprache)
Background
RTS,S/AS01 vaccine efficacy (VE) was previously shown as lower in African adults than in malaria-naive US adults, potentially due to concurrent Plasmodium falciparum infections. We investigated whether treatment of infection prior to vaccination would lead to improved VE and immunogenicity.
Methods
A phase 2b study in Kenyan adults evaluated the efficacy of RTS,S/AS01E in conjunction with antimalarial chemopreventive drugs. Participants, grouped by baseline presence or absence of P. falciparum infections, were randomized to receive RTS,S/AS01E or rabies vaccine. Four groups received antimalarial drugs prior to immunization and were followed for 6 months to assess P. falciparum infection. We included an additional group not treated with antimalarial drugs for immunological assessment.
Results
VE (RTS,S/AS01E vs rabies vaccine) was 34.8% (95% confidence interval [CI], 8.9% to 53.4%) and −24.0% (95% CI, −97% to 22.4%) in baseline P. falciparum-positive and P. falciparum-negative participants, respectively. In RTS,S/AS01E recipients, there were no statistical differences in anticircumsporozoite (anti-CS) antibody titers in baseline P. falciparum-positive or P. falciparum-negative participants, or in susceptibility to infection during the postvaccination follow-up period. Drug treatment did not improve anti-CS antibody titers.
Conclusions
Treating P. falciparum infections during vaccination does not result in increased VE. Anti-CS antibody responses to vaccination do not differ with baseline P. falciparum infection status, drug treatment, or susceptibility to P. falciparum infections. Clinical Trials Registration NCT04661579; PACTR202006896481432.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kombewa Clinical Research Centre, Kenya Medical Research Institute/US Army Medical Research Directorate-Africa, Kisumu, Kenya.
- Center for Vaccine Innovation and Access, PATH, Washington, District of Columbia, USA; Seattle, Washington, USA; Nairobi, Kenya; and Geneva, Switzerland.
- Biologics Research & Development, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
- Human Immunology Laboratory, International AIDS Vaccine Initiative, London, United Kingdom.
- Vaccine Clinical R&D, GlaxoSmithKline, Wavre, Belgium.
ORCID-Profile: Nathanial K Copeland, Ben Andagalu, Emily Locke, Elke S Bergmann-Leitner, Mike Raine, Chris Gast, John J Aponte
Förderung
- Bill and Melinda Gates Foundation
- Gates Foundation
Zitieren
APA
Copeland, N. K., Otieno, L., Otieno, J. D., Otieno, S., Chira, S., Ivinson, K., Onyango, I., Wasuna, R., Akala, H., Onditi, A., Sifuna, P., Andagalu, B., Oyugi, R., Omondi, M., Amoit, S., Locke, E., Gregory, S., Bergmann-Leitner, E. S., Pindolia, H., …, & Lee, C. K. (2025). Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum -Exposed, Drug-Treated Kenyan Adults. The Journal of Infectious Diseases, 232(3), e372-e382. https://doi.org/10.1093/infdis/jiaf274
Vancouver
Copeland NK, Otieno L, Otieno JD, Otieno S, Chira S, Ivinson K, et al. Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum -Exposed, Drug-Treated Kenyan Adults. The Journal of Infectious Diseases. 2025;232(3):e372-e382. doi:10.1093/infdis/jiaf274
BibTeX
@article{Copeland2025,
author = {Copeland, Nathanial K and Otieno, Lucas and Otieno, June Doryne and Otieno, Solomon and Chira, Salome and Ivinson, Karen and Onyango, Irene and Wasuna, Ruth and Akala, Hoseah and Onditi, Amos and Sifuna, Peter and Andagalu, Ben and Oyugi, Roselyne and Omondi, Mary and Amoit, Stellah and Locke, Emily and Gregory, Scott and Bergmann-Leitner, Elke S and Pindolia, Hema and Raine, Mike and Gast, Chris and Mercer, Laina D and Aponte, John J and Lievens, Marc and Ockenhouse, Christian F and Lee, Cynthia K},
title = {Efficacy of RTS,S/AS01E Only Seen in Baseline Parasitemic and Not Baseline Aparasitemic Plasmodium falciparum -Exposed, Drug-Treated Kenyan Adults},
journal = {The Journal of Infectious Diseases},
year = {2025},
volume = {232},
number = {3},
pages = {e372--e382},
doi = {10.1093/infdis/jiaf274}
}
EUVIMED